APA

Brandon E. F. A., Bulder A. S., van Engelen J. G. M., Mahieu C. M., Mennes W. C., Pronk M. E. J., Rietveld A. G., van de Ven B. M., Ten Voorde S. E. C. G., Wolterink G., Slob W., Zeilmaker M. J. & Bessems J. G. M. (20140610). Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?. : Regulatory toxicology and pharmacology : RTP.

Chicago

Brandon E F A, Bulder A S, van Engelen J G M, Mahieu C M, Mennes W C, Pronk M E J, Rietveld A G, van de Ven B M, Ten Voorde S E C G, Wolterink G, Slob W, Zeilmaker M J and Bessems J G M. 20140610. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?. : Regulatory toxicology and pharmacology : RTP.

Harvard

Brandon E. F. A., Bulder A. S., van Engelen J. G. M., Mahieu C. M., Mennes W. C., Pronk M. E. J., Rietveld A. G., van de Ven B. M., Ten Voorde S. E. C. G., Wolterink G., Slob W., Zeilmaker M. J. and Bessems J. G. M. (20140610). Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?. : Regulatory toxicology and pharmacology : RTP.

MLA

Brandon E F A, Bulder A S, van Engelen J G M, Mahieu C M, Mennes W C, Pronk M E J, Rietveld A G, van de Ven B M, Ten Voorde S E C G, Wolterink G, Slob W, Zeilmaker M J and Bessems J G M. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?. : Regulatory toxicology and pharmacology : RTP. 20140610.